Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wrist sensor cut the dose of ICU muscle relaxants?

NCT ID NCT07807046

Disease control Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether a monitor that measures muscle response can guide the dose of the muscle relaxant atracurium in intensive care unit patients who need a continuous drip for more than 48 hours. Researchers will compare a group whose dose is adjusted using the monitor to a group receiving usual bedside checks. The goal is to see if the monitor lowers the total amount of medicine needed and reduces related complications. Participants receive atracurium as part of their standard ICU care, and those in the monitor group have a small sensor placed on the wrist and hand.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atracurium infusion guided by an electromyography-based muscle response monitor
What this could lead to
If it works, this approach could lower the amount of muscle relaxant ICU patients need, potentially reducing side effects while keeping the same level of care.
What could go wrong
The trial is early and small, and results may not apply to all ICU patients. The monitor might not reliably reduce complications, and dosing errors could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult ICU patients (≥ 20 years of age) requiring continuous atracurium infusion for more than 48 hours due to any of the following conditions: * Moderate-to-severe ARDS (PaO₂/FiO₂ ratio ≤ 150) * Post-cardiac arrest care with device-controlled TTM (intravascular or surface cooling system) * Veno-venous (VV) or veno-arterial (VA) ECMO support Exclusion Criteria: * Patients aged under 20 years * Pregnant patients * Patients with known allergy to atracurium * Patients with a do-not-intervention order due to terminal disease * Patients with severe asthma, owing to the potential for atracurium-induced histamine release * Patients or their families who refuse to participate in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome tetralogy of fallot trichotillomania

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS ECMO Neuromuscular blockade monitoring TTM

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fu-Jen Catholic University Hospital

    RECRUITING

    New Taipei City, 243, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.